• MEI Pharma, BeiGene Collaborate on ME-401, Zanubrutinib Combination americanpharmaceuticalreview
    October 12, 2018
    MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of pati
PharmaSources Customer Service